Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells

Tatsushi Suwa; Masakazu Ueda; Hiromitsu Jinno; Soji Ozawa; Yuko Kitagawa; Nobutoshi Ando; Masaki Kitajima

Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells

Tatsushi Suwa, Masakazu Ueda, Hiromitsu Jinno, Soji Ozawa, Yuko Kitagawa, Nobutoshi Ando, Masaki Kitajima

Vice-President

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

We have conjugated the murine monoclonal antibody (528) against the human epidermal growth factor receptor (EGFR) to mammalian pancreatic ribonuclease (RNase) via N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolene (2-IT). The conjugate showed dose-dependent cytotoxicity against EGFR-producing squamous cancer cells (A431, TE8, TE5, Ca9-22) and no detectable cytotoxicity against EGFR-deficient small-cell lung cancer cells (H69). The cytotoxicity of the conjugate was positively correlated with the EGFR numbers of each cell line. The addition of excess 528 antibody to the medium protected A431 cells from the conjugate cytotoxicity. This immuno-conjugate might be useful for targeted treatment of squamous cell carcinomas hyperexpressing EGFR.

Original language	English
Pages (from-to)	4161-4165
Number of pages	5
Journal	Anticancer research
Volume	19
Issue number	5 B
Publication status	Published - 1999 Dec 25

Keywords

Conjugate
Epidermal growth factor receptor
Ribonuclease

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{331516ad44684a8f9e70d5891d8d86b3,

title = "Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells",

abstract = "We have conjugated the murine monoclonal antibody (528) against the human epidermal growth factor receptor (EGFR) to mammalian pancreatic ribonuclease (RNase) via N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolene (2-IT). The conjugate showed dose-dependent cytotoxicity against EGFR-producing squamous cancer cells (A431, TE8, TE5, Ca9-22) and no detectable cytotoxicity against EGFR-deficient small-cell lung cancer cells (H69). The cytotoxicity of the conjugate was positively correlated with the EGFR numbers of each cell line. The addition of excess 528 antibody to the medium protected A431 cells from the conjugate cytotoxicity. This immuno-conjugate might be useful for targeted treatment of squamous cell carcinomas hyperexpressing EGFR.",

keywords = "Conjugate, Epidermal growth factor receptor, Ribonuclease",

author = "Tatsushi Suwa and Masakazu Ueda and Hiromitsu Jinno and Soji Ozawa and Yuko Kitagawa and Nobutoshi Ando and Masaki Kitajima",

year = "1999",

month = dec,

day = "25",

language = "English",

volume = "19",

pages = "4161--4165",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5 B",

}

TY - JOUR

T1 - Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells

AU - Suwa, Tatsushi

AU - Ueda, Masakazu

AU - Jinno, Hiromitsu

AU - Ozawa, Soji

AU - Kitagawa, Yuko

AU - Ando, Nobutoshi

AU - Kitajima, Masaki

PY - 1999/12/25

Y1 - 1999/12/25

N2 - We have conjugated the murine monoclonal antibody (528) against the human epidermal growth factor receptor (EGFR) to mammalian pancreatic ribonuclease (RNase) via N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolene (2-IT). The conjugate showed dose-dependent cytotoxicity against EGFR-producing squamous cancer cells (A431, TE8, TE5, Ca9-22) and no detectable cytotoxicity against EGFR-deficient small-cell lung cancer cells (H69). The cytotoxicity of the conjugate was positively correlated with the EGFR numbers of each cell line. The addition of excess 528 antibody to the medium protected A431 cells from the conjugate cytotoxicity. This immuno-conjugate might be useful for targeted treatment of squamous cell carcinomas hyperexpressing EGFR.

AB - We have conjugated the murine monoclonal antibody (528) against the human epidermal growth factor receptor (EGFR) to mammalian pancreatic ribonuclease (RNase) via N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolene (2-IT). The conjugate showed dose-dependent cytotoxicity against EGFR-producing squamous cancer cells (A431, TE8, TE5, Ca9-22) and no detectable cytotoxicity against EGFR-deficient small-cell lung cancer cells (H69). The cytotoxicity of the conjugate was positively correlated with the EGFR numbers of each cell line. The addition of excess 528 antibody to the medium protected A431 cells from the conjugate cytotoxicity. This immuno-conjugate might be useful for targeted treatment of squamous cell carcinomas hyperexpressing EGFR.

KW - Conjugate

KW - Epidermal growth factor receptor

KW - Ribonuclease

UR - http://www.scopus.com/inward/record.url?scp=0032786721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032786721&partnerID=8YFLogxK

M3 - Article

C2 - 10628369

AN - SCOPUS:0032786721

SN - 0250-7005

VL - 19

SP - 4161

EP - 4165

JO - Anticancer Research

JF - Anticancer Research

IS - 5 B

ER -

Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this